A randomized, phase II study of GW786034 (pazopanib) in stage D0 relapsed androgen sensitive prostate cancer following limited GnRH [gonadotropin-releasing hormone] agonist therapy.

Trial Profile

A randomized, phase II study of GW786034 (pazopanib) in stage D0 relapsed androgen sensitive prostate cancer following limited GnRH [gonadotropin-releasing hormone] agonist therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2016

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Mar 2012 Results published in Prostate Cancer and Prostatic Diseases.
    • 16 Aug 2011 Actual end date (December 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top